{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:44:36Z","timestamp":1780631076116,"version":"3.54.1"},"reference-count":239,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ctrv.2025.103061","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T16:03:11Z","timestamp":1764345791000},"page":"103061","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Cellular senescence: A novel mechanism of therapeutic resistance in prostate cancer"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1582-6488","authenticated-orcid":false,"given":"Claire","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Hadfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Pinho-Schwermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaolei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra den","family":"Hollander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sendurai A.","family":"Mani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila A.","family":"Seyhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariana","family":"Santopietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Mega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafik S.","family":"El-Deiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5468-1126","authenticated-orcid":false,"given":"Benedito A.","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.ctrv.2025.103061_b0005","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The diagnosis and treatment of prostate cancer: a review","volume":"317","author":"Litwin","year":"2017","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ctrv.2025.103061_b0010","first-page":"1","article-title":"Combining androgen deprivation and radiation therapy in the treatment of localised prostate cancer: Summary of level 1 evidence and current gaps in knowledge","volume":"37","author":"Baude","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103061_b0015","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/cncr.31833","article-title":"Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers","volume":"125","author":"Sundi","year":"2019","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103061_b0020","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.ijrobp.2008.05.009","article-title":"Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors","volume":"73","author":"Nguyen","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103061_b0025","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion","volume":"6","author":"Harris","year":"2009","journal-title":"Nat Clin Pract Urol"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103061_b0030","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0035","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40164-023-00444-9","article-title":"Recent advances and future perspectives in the therapeutics of prostate cancer","volume":"12","author":"Varaprasad","year":"2023","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103061_b0040","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","article-title":"Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial","volume":"19","author":"Chi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103061_b0045","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41391-023-00725-8","article-title":"Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population","volume":"27","author":"Freedland","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ctrv.2025.103061_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2025.149774","article-title":"Therapy-induced senescence in prostate cancer: mechanisms, therapeutic strategies, and clinical implications","volume":"972","author":"Bacca","year":"2025","journal-title":"Gene"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103061_b0055","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","article-title":"Exploiting senescence for the treatment of cancer","volume":"22","author":"Wang","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2025.103061_b0060","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","article-title":"The senescence-associated secretory phenotype: the dark side of tumor suppression","volume":"5","author":"Coppe","year":"2010","journal-title":"Annu Rev Pathol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103061_b0065","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41571-022-00668-4","article-title":"Senescence and cancer - role and therapeutic opportunities","volume":"19","author":"Schmitt","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103061_b0070","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1535-7163.MCT-21-0604","article-title":"Olaparib-Induced Senescence is Bypassed through G2-M Checkpoint Override in Olaparib-Resistant Prostate Cancer","volume":"21","author":"Lombard","year":"2022","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0075","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s41232-022-00197-8","article-title":"The roles and mechanisms of senescence-associated secretory phenotype (SASP): can it be controlled by senolysis?","volume":"42","author":"Ohtani","year":"2022","journal-title":"Inflamm Regen"},{"key":"10.1016\/j.ctrv.2025.103061_b0080","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/cells11040672","article-title":"Epigenetic Regulation of Cellular Senescence","volume":"11","author":"Crouch","year":"2022","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103061_b0085","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1152\/physrev.00020.2018","article-title":"Cellular Senescence: Aging, Cancer, and Injury","volume":"99","author":"Calcinotto","year":"2019","journal-title":"Physiol Rev"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103061_b0090","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.cmet.2018.03.009","article-title":"Senescence Elicits Stemness: a Surprising Mechanism for Cancer Relapse","volume":"27","author":"Dou","year":"2018","journal-title":"Cell Metab"},{"issue":"7686","key":"10.1016\/j.ctrv.2025.103061_b0095","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature25167","article-title":"Senescence-associated reprogramming promotes cancer stemness","volume":"553","author":"Milanovic","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0100","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12943-024-02096-7","article-title":"Cellular senescence and SASP in tumor progression and therapeutic opportunities","volume":"23","author":"Dong","year":"2024","journal-title":"Mol Cancer"},{"issue":"20","key":"10.1016\/j.ctrv.2025.103061_b0105","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/jnci\/djq364","article-title":"Therapy-induced senescence in cancer","volume":"102","author":"Ewald","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0110","article-title":"Escape from senescence: revisiting cancer therapeutic strategies","volume":"9","author":"Zampetidis","year":"2022","journal-title":"Mol Cell Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0115","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13014-022-02184-2","article-title":"Radiation-induced senescence: therapeutic opportunities","volume":"18","author":"Kim","year":"2023","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctrv.2025.103061_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102032","article-title":"The redox-senescence axis and its therapeutic targeting","volume":"45","author":"Ngoi","year":"2021","journal-title":"Redox Biol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103061_b0125","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.tcb.2018.02.001","article-title":"Hallmarks of Cellular Senescence","volume":"28","author":"Hernandez-Segura","year":"2018","journal-title":"Trends Cell Biol"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103061_b0130","doi-asserted-by":"crossref","DOI":"10.3390\/cells10071740","article-title":"The Emergence of Senescent Surface Biomarkers as Senotherapeutic Targets","volume":"10","author":"Rossi","year":"2021","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103061_b0135","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2024.13286","article-title":"Cellular senescence in metastatic prostate cancer: a therapeutic opportunity or challenge (Review)","volume":"30","author":"Jin","year":"2024","journal-title":"Mol Med Rep"},{"issue":"7051","key":"10.1016\/j.ctrv.2025.103061_b0140","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nature03841","article-title":"Oncogene-induced senescence as an initial barrier in lymphoma development","volume":"436","author":"Braig","year":"2005","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103061_b0145","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1172\/JCI95148","article-title":"Mechanisms and functions of cellular senescence","volume":"128","author":"Herranz","year":"2018","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103061_b0150","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrm3823","article-title":"Cellular senescence: from physiology to pathology","volume":"15","author":"Munoz-Espin","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103061_b0155","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ceb.2010.07.013","article-title":"Oncogene-induced senescence: the bright and dark side of the response","volume":"22","author":"Gorgoulis","year":"2010","journal-title":"Curr Opin Cell Biol"},{"issue":"46","key":"10.1016\/j.ctrv.2025.103061_b0160","doi-asserted-by":"crossref","first-page":"E6301","DOI":"10.1073\/pnas.1515386112","article-title":"JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age","volume":"112","author":"Xu","year":"2015","journal-title":"PNAS"},{"key":"10.1016\/j.ctrv.2025.103061_b0165","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.mad.2017.08.005","article-title":"The senescent bystander effect is caused by ROS-activated NF-kappaB signalling","volume":"170","author":"Nelson","year":"2018","journal-title":"Mech Ageing Dev"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103061_b0170","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.cell.2008.03.039","article-title":"Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network","volume":"133","author":"Kuilman","year":"2008","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103061_b0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003728","article-title":"Dynamic modelling of pathways to cellular senescence reveals strategies for targeted interventions","volume":"10","author":"Dalle Pezze","year":"2014","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.ctrv.2025.103061_b0180","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/msb.2010.5","article-title":"Feedback between p21 and reactive oxygen production is necessary for cell senescence","volume":"6","author":"Passos","year":"2010","journal-title":"Mol Syst Biol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103061_b0185","doi-asserted-by":"crossref","first-page":"864","DOI":"10.4161\/cbt.7.6.5861","article-title":"A chemotherapy-associated senescence bystander effect in breast cancer cells","volume":"7","author":"Di","year":"2008","journal-title":"Cancer Biol Ther"},{"issue":"30","key":"10.1016\/j.ctrv.2025.103061_b0190","doi-asserted-by":"crossref","first-page":"12052","DOI":"10.1073\/pnas.1120437109","article-title":"Plasminogen activator inhibitor 1\u2013insulin-like growth factor binding protein 3 cascade regulates stress-induced senescence","volume":"109","author":"Elzi","year":"2012","journal-title":"PNAS"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103061_b0195","doi-asserted-by":"crossref","first-page":"932","DOI":"10.18632\/aging.100520","article-title":"IL1- and TGFbeta-Nox4 signaling, oxidative stress and DNA damage response are shared features of replicative, oncogene-induced, and drug-induced paracrine 'bystander senescence'","volume":"4","author":"Hubackova","year":"2012","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0200","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/s41467-018-03299-5","article-title":"Paracrine cellular senescence exacerbates biliary injury and impairs regeneration","volume":"9","author":"Ferreira-Gonzalez","year":"2018","journal-title":"Nat Commun"},{"issue":"19","key":"10.1016\/j.ctrv.2025.103061_b0205","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.4161\/cc.6.19.4754","article-title":"DNA damage response as an anti-cancer barrier: damage threshold and the concept of 'conditional haploinsufficiency'","volume":"6","author":"Bartek","year":"2007","journal-title":"Cell Cycle"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103061_b0210","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1158\/2159-8290.CD-22-0528","article-title":"Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity","volume":"13","author":"Chen","year":"2023","journal-title":"Cancer Discov"},{"issue":"7128","key":"10.1016\/j.ctrv.2025.103061_b0215","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature05529","article-title":"Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas","volume":"445","author":"Xue","year":"2007","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0220","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12943-024-02022-x","article-title":"JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression","volume":"23","author":"Redmer","year":"2024","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0225","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12943-024-02114-8","article-title":"Cell-autonomous IL6ST activation suppresses prostate cancer development via STAT3\/ARF\/p53-driven senescence and confers an immune-active tumor microenvironment","volume":"23","author":"Sternberg","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ctrv.2025.103061_b0230","doi-asserted-by":"crossref","unstructured":"De Blander, H., et al., Cellular Plasticity: A Route to Senescence Exit and Tumorigenesis. Cancers (Basel), 2021. 13(18).","DOI":"10.3390\/cancers13184561"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103061_b0235","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cell.2013.03.020","article-title":"Non-cell-autonomous tumor suppression by p53","volume":"153","author":"Lujambio","year":"2013","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103061_b0240","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1084\/jem.20130783","article-title":"p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells","volume":"210","author":"Iannello","year":"2013","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103061_b0245","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1158\/0008-5472.CAN-24-2219","article-title":"A critical Appraisal of the Utility of Targeting Therapy-Induced Senescence for Cancer Treatment","volume":"85","author":"Saleh","year":"2025","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103061_b0250","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1002\/1878-0261.13042","article-title":"Overcoming the senescence-associated secretory phenotype (SASP): a complex mechanism of resistance in the treatment of cancer","volume":"15","author":"Chambers","year":"2021","journal-title":"Mol Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103061_b0255","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.trecan.2020.05.004","article-title":"Senescent Cells in Cancer Therapy: Friends or Foes?","volume":"6","author":"Wang","year":"2020","journal-title":"Trends Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103061_b0260","doi-asserted-by":"crossref","DOI":"10.3892\/or.2022.8349","article-title":"Dual STAT\u20113 and IL\u20116R inhibition with stattic and tocilizumab decreases migration, invasion and proliferation of prostate cancer cells by targeting the IL\u20116\/IL\u20116R\/STAT\u20113 axis","volume":"48","author":"Mendez-Clemente","year":"2022","journal-title":"Oncol Rep"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0265","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12307-011-0069-4","article-title":"Epithelial-mesenchymal transition induced by senescent fibroblasts","volume":"5","author":"Laberge","year":"2012","journal-title":"Cancer Microenviron"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103061_b0270","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.eururo.2016.06.018","article-title":"Expression of STAT3 in Prostate Cancer Metastases","volume":"71","author":"Don-Doncow","year":"2017","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103061_b0275","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1593\/neo.13706","article-title":"The IL-6\/JAK\/Stat3 feed-forward loop drives tumorigenesis and metastasis","volume":"15","author":"Chang","year":"2013","journal-title":"Neoplasia"},{"key":"10.1016\/j.ctrv.2025.103061_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.04.003","article-title":"Senescent cell clearance by the immune system: Emerging therapeutic opportunities","volume":"40","author":"Prata","year":"2018","journal-title":"Semin Immunol"},{"issue":"7525","key":"10.1016\/j.ctrv.2025.103061_b0285","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nature13638","article-title":"Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer","volume":"515","author":"Di Mitri","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0290","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.smim.2014.01.008","article-title":"The two faces of IL-6 in the tumor microenvironment","volume":"26","author":"Fisher","year":"2014","journal-title":"Semin Immunol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103061_b0295","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41556-024-01465-0","article-title":"p16-dependent increase of PD-L1 stability regulates immunosurveillance of senescent cells","volume":"26","author":"Majewska","year":"2024","journal-title":"Nat Cell Biol"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103061_b0300","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/imcb.12812","article-title":"The up-regulation of PD-L1 during boningmycin-induced senescence in human cancer cells depends on the activation of the JAK\/STAT signaling pathway mediated by SASP","volume":"102","author":"Chen","year":"2024","journal-title":"Immunol Cell Biol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0305","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-018-0629-x","article-title":"T cell senescence and CAR-T cell exhaustion in hematological malignancies","volume":"11","author":"Kasakovski","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103061_b0310","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1158\/0008-5472.CAN-18-3437","article-title":"Tumor Cell Escape from Therapy-Induced Senescence as a Model of Disease Recurrence after Dormancy","volume":"79","author":"Saleh","year":"2019","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0315","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12943-025-02323-9","article-title":"Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment","volume":"24","author":"Liu","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ctrv.2025.103061_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116781","article-title":"Cancer stem cell (CSC) resistance drivers","volume":"234","author":"Najafi","year":"2019","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0325","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41392-024-01851-y","article-title":"Cancer stem cells: advances in knowledge and implications for cancer therapy","volume":"9","author":"Chu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103061_b0330","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41571-023-00815-5","article-title":"Drug-tolerant persister cells in cancer: the cutting edges and future directions","volume":"20","author":"Pu","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103061_b0335","article-title":"Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategies","volume":"16","author":"Li","year":"2025","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103061_b0340","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41588-022-01047-6","article-title":"H3K27me3 conditions chemotolerance in triple-negative breast cancer","volume":"54","author":"Marsolier","year":"2022","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0345","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103061_b0350","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.tem.2023.11.005","article-title":"Metabolic challengers selecting tumor-persistent cells","volume":"35","author":"Mancini","year":"2024","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2025.103061_b0355","article-title":"A Transient Metabolic State in Melanoma Persister Cells Mediated by Chemotherapeutic Treatments","volume":"8","author":"Karki","year":"2021","journal-title":"Front Mol Biosci"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0360","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1038\/s41467-020-18442-4","article-title":"Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0365","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1038\/s41467-018-05626-2","article-title":"Notch3-dependent beta-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC","volume":"9","author":"Arasada","year":"2018","journal-title":"Nat Commun"},{"issue":"22","key":"10.1016\/j.ctrv.2025.103061_b0370","doi-asserted-by":"crossref","first-page":"9479","DOI":"10.1158\/0008-5472.CAN-08-1643","article-title":"Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations","volume":"68","author":"Yano","year":"2008","journal-title":"Cancer Res"},{"issue":"24","key":"10.1016\/j.ctrv.2025.103061_b0375","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.4161\/15384101.2014.988033","article-title":"Resistance to targeted cancer drugs through hepatocyte growth factor signaling","volume":"13","author":"Heynen","year":"2014","journal-title":"Cell Cycle"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103061_b0380","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","article-title":"Cancer drug-tolerant persister cells: from biological questions to clinical opportunities","volume":"24","author":"Russo","year":"2024","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103061_b0385","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2021.07.017","article-title":"Mechanism of Drug Tolerant Persister Cancer Cells: the Landscape and Clinical Implication for Therapy","volume":"16","author":"Mikubo","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0390","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","article-title":"Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway","volume":"37","author":"Kurppa","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2025.103061_b0395","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.canlet.2021.09.037","article-title":"Prostate cancer dormancy and recurrence","volume":"524","author":"Cackowski","year":"2022","journal-title":"Cancer Lett"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103061_b0400","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1078-0432.CCR-08-1754","article-title":"Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence","volume":"15","author":"Morgan","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103061_b0405","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1038\/s41591-025-03877-3","article-title":"Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial","volume":"31","author":"DeMichele","year":"2025","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103061_b0410","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cncr.26202","article-title":"Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancer","volume":"118","author":"Hall","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103061_b0415","doi-asserted-by":"crossref","first-page":"R117","DOI":"10.1186\/bcr3242","article-title":"Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival","volume":"14","author":"Mathiesen","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103061_b0420","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-24-4809","article-title":"PRDM16 Regulates Prostate Cancer Cell Dormancy and Prevents Bone Metastatic Outgrowth","author":"Nasr","year":"2025","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103061_b0425","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1158\/0008-5472.CAN-17-1051","article-title":"Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGFbetaRIII-p38MAPK-pS249\/T252RB Pathway","volume":"78","author":"Yu-Lee","year":"2018","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.ctrv.2025.103061_b0430","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1084\/jem.20110840","article-title":"Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone","volume":"208","author":"Kobayashi","year":"2011","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103061_b0435","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/jcb.25582","article-title":"Growth Arrest-specific 6 (GAS6) Promotes Prostate Cancer Survival by G(1) Arrest\/S phase Delay and Inhibition of Apoptosis during Chemotherapy in Bone Marrow","volume":"117","author":"Lee","year":"2016","journal-title":"J Cell Biochem"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103061_b0440","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061873","article-title":"GAS6 receptor status is associated with dormancy and bone metastatic tumor formation","volume":"8","author":"Taichman","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103061_b0445","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1084\/jem.20180661","article-title":"Wnt5a induces and maintains prostate cancer cells dormancy in bone","volume":"216","author":"Ren","year":"2019","journal-title":"J Exp Med"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103061_b0450","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrc2256","article-title":"Models, mechanisms and clinical evidence for cancer dormancy","volume":"7","author":"Aguirre-Ghiso","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0455","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10555-023-10089-z","article-title":"Could senescence phenotypes strike the balance to promote tumor dormancy?","volume":"42","author":"Chiu","year":"2023","journal-title":"Cancer Metastasis Rev"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103061_b0460","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1083\/jcb.201904051","article-title":"Chemotherapy-induced senescent cancer cells engulf other cells to enhance their survival","volume":"218","author":"Tonnessen-Murray","year":"2019","journal-title":"J Cell Biol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103061_b0465","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1667\/RADE-20-00009","article-title":"The Roles of Autophagy and Senescence in the Tumor Cell Response to Radiation","volume":"194","author":"Patel","year":"2020","journal-title":"Radiat Res"},{"key":"10.1016\/j.ctrv.2025.103061_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215850","article-title":"Transformed cells after senescence give rise to more severe tumor phenotypes than transformed non-senescent cells","volume":"546","author":"Palazzo","year":"2022","journal-title":"Cancer Lett"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103061_b0475","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0092-8674(03)00401-X","article-title":"Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence","volume":"113","author":"Narita","year":"2003","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103061_b0480","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1101\/gad.271882.115","article-title":"MLL1 is essential for the senescence-associated secretory phenotype","volume":"30","author":"Capell","year":"2016","journal-title":"Genes Dev"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103061_b0485","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202008101","article-title":"DOT1L modulates the senescence-associated secretory phenotype through epigenetic regulation of IL1A","volume":"220","author":"Leon","year":"2021","journal-title":"J Cell Biol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103061_b0490","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1158\/2159-8290.CD-16-0217","article-title":"BRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance","volume":"6","author":"Tasdemir","year":"2016","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103061_b0495","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1158\/1078-0432.CCR-04-1462","article-title":"Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response","volume":"11","author":"Elmore","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103061_b0500","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1158\/0008-5472.CAN-04-1270","article-title":"Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers","volume":"65","author":"Roberson","year":"2005","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103061_b0505","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s13402-024-01018-5","article-title":"Senolytics: charting a new course or enhancing existing anti-tumor therapies?","volume":"48","author":"Czajkowski","year":"2025","journal-title":"Cell Oncol (Dordr)"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103061_b0510","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/cdd.2013.86","article-title":"MEK drives cyclin D1 hyperelevation during geroconversion","volume":"20","author":"Leontieva","year":"2013","journal-title":"Cell Death Differ"},{"issue":"20","key":"10.1016\/j.ctrv.2025.103061_b0515","doi-asserted-by":"crossref","first-page":"7917","DOI":"10.1158\/0008-5472.CAN-08-2510","article-title":"Senescence-associated oxidative DNA damage promotes the generation of neoplastic cells","volume":"69","author":"Gosselin","year":"2009","journal-title":"Cancer Res"},{"issue":"5\u20136","key":"10.1016\/j.ctrv.2025.103061_b0520","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1290\/1543-706X(2004)40<150:SCTKDF>2.0.CO;2","article-title":"Spontaneous cell transformation: karyoplasts derived from multinucleated cells produce new cell growth in senescent human epithelial cell cultures","volume":"40","author":"Walen","year":"2004","journal-title":"In Vitro Cell Dev Biol Anim"},{"issue":"3\u20134","key":"10.1016\/j.ctrv.2025.103061_b0525","doi-asserted-by":"crossref","first-page":"60","DOI":"10.18632\/genesandcancer.102","article-title":"Coevolution of neoplastic epithelial cells and multilineage stroma via polyploid giant cells during immortalization and transformation of mullerian epithelial cells","volume":"7","author":"Zhang","year":"2016","journal-title":"Genes Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103061_b0530","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/ijc.27810","article-title":"Polyploidy road to therapy-induced cellular senescence and escape","volume":"132","author":"Wang","year":"2013","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103061_b0535","doi-asserted-by":"crossref","first-page":"e1711","DOI":"10.1038\/cddis.2015.71","article-title":"In vitro evidence for senescent multinucleated melanocytes as a source for tumor-initiating cells","volume":"6","author":"Leikam","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ctrv.2025.103061_b0540","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1475-2867-6-25","article-title":"Stem cells, senescence, neosis and self-renewal in cancer","volume":"6","author":"Rajaraman","year":"2006","journal-title":"Cancer Cell Int"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103061_b0545","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/path.6164","article-title":"Escape from senescence: molecular basis and therapeutic ramifications","volume":"260","author":"Evangelou","year":"2023","journal-title":"J Pathol"},{"key":"10.1016\/j.ctrv.2025.103061_b0550","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.semcancer.2020.12.010","article-title":"Targeting tumor cell senescence and polyploidy as potential therapeutic strategies","volume":"81","author":"Saleh","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103061_b0555","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.neo.2015.11.008","article-title":"Polyploidy Formation in Doxorubicin-Treated Cancer Cells can Favor Escape from Senescence","volume":"17","author":"Mosieniak","year":"2015","journal-title":"Neoplasia"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103061_b0560","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/ijc.25482","article-title":"Survivin and escaping in therapy-induced cellular senescence","volume":"128","author":"Wang","year":"2011","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103061_b0565","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41419-017-0209-y","article-title":"Regulation of senescence escape by the cdk4-EZH2-AP2M1 pathway in response to chemotherapy","volume":"9","author":"Le Duff","year":"2018","journal-title":"Cell Death Dis"},{"issue":"34","key":"10.1016\/j.ctrv.2025.103061_b0570","doi-asserted-by":"crossref","first-page":"E5024","DOI":"10.1073\/pnas.1602379113","article-title":"Derepression of hTERT gene expression promotes escape from oncogene-induced cellular senescence","volume":"113","author":"Patel","year":"2016","journal-title":"PNAS"},{"issue":"17","key":"10.1016\/j.ctrv.2025.103061_b0575","doi-asserted-by":"crossref","first-page":"20962","DOI":"10.18632\/aging.203495","article-title":"Glutamine promotes escape from therapy-induced senescence in tumor cells","volume":"13","author":"Pacifico","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103061_b0580","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cmet.2019.11.020","article-title":"A Variant of SLC1A5 is a Mitochondrial Glutamine Transporter for Metabolic Reprogramming in Cancer Cells","volume":"31","author":"Yoo","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.ctrv.2025.103061_b0585","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/bs.acr.2021.01.004","article-title":"The role of autophagy in escaping therapy-induced polyploidy\/senescence","volume":"150","author":"Dudkowska","year":"2021","journal-title":"Adv Cancer Res"},{"issue":"21","key":"10.1016\/j.ctrv.2025.103061_b0590","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15215114","article-title":"Advancements and Obstacles of PARP Inhibitors in Gastric Cancer","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0595","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.celrep.2014.08.044","article-title":"Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity","volume":"9","author":"Toso","year":"2014","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0600","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ccell.2020.10.012","article-title":"Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis","volume":"39","author":"Guccini","year":"2021","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103061_b0605","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1148\/rg.2021200171","article-title":"Second Malignancies after Radiation Therapy: Update on Pathogenesis and Cross-sectional Imaging Findings","volume":"41","author":"Khanna","year":"2021","journal-title":"Radiographics"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0610","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12943-025-02310-0","article-title":"Therapy-induced senescence is a transient drug resistance mechanism in breast cancer","volume":"24","author":"Bajtai","year":"2025","journal-title":"Mol Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103061_b0615","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra1204892","article-title":"The implications of clonal genome evolution for cancer medicine","volume":"368","author":"Aparicio","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103061_b0620","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026617","article-title":"Treatment-Induced Mutagenesis and Selective pressures Sculpt Cancer Evolution","volume":"7","author":"Venkatesan","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103061_b0625","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/acel.12518","article-title":"Small molecule compounds that induce cellular senescence","volume":"15","author":"Petrova","year":"2016","journal-title":"Aging Cell"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103061_b0630","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.3802\/jgo.2019.30.e26","article-title":"Olaparib induced senescence under P16 or P53 dependent manner in ovarian cancer","volume":"30","author":"Wang","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.ctrv.2025.103061_b0635","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","article-title":"The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer","volume":"108","author":"Smith","year":"2010","journal-title":"Adv Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103061_b0640","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.critrevonc.2014.02.003","article-title":"Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity","volume":"91","author":"Schutz","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0645","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41420-021-00554-5","article-title":"Platinum drugs and taxanes: can we overcome resistance?","volume":"7","author":"Sazonova","year":"2021","journal-title":"Cell Death Discov"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103061_b0650","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1158\/2159-8290.CD-16-0241","article-title":"Cellular Senescence Promotes adverse Effects of Chemotherapy and Cancer Relapse","volume":"7","author":"Demaria","year":"2017","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103061_b0655","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1593\/neo.05250","article-title":"The identification of senescence-specific genes during the induction of senescence in prostate cancer cells","volume":"7","author":"Schwarze","year":"2005","journal-title":"Neoplasia"},{"issue":"21","key":"10.1016\/j.ctrv.2025.103061_b0660","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1002\/1878-0261.13312","article-title":"Targeting senescence as an anticancer therapy","volume":"16","author":"Bousset","year":"2022","journal-title":"Mol Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103061_b0665","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103061_b0670","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points","volume":"14","author":"Tannock","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103061_b0675","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-1-4939-6670-7_3","article-title":"Cellular Model of p21-Induced Senescence","volume":"1534","author":"Shtutman","year":"2017","journal-title":"Methods Mol Biol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103061_b0680","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1161\/ATVBAHA.117.309451","article-title":"Plasminogen Activator Inhibitor-1 is a Marker and a Mediator of Senescence","volume":"37","author":"Vaughan","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103061_b0685","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1371\/journal.pbio.0060301","article-title":"Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor","volume":"6","author":"Coppe","year":"2008","journal-title":"PLoS Biol"},{"key":"10.1016\/j.ctrv.2025.103061_b0690","doi-asserted-by":"crossref","first-page":"S458","DOI":"10.1016\/j.annonc.2023.09.1876","article-title":"690P - Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I\/II study","volume":"34","author":"Patel","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103061_b0695","first-page":"S1264","article-title":"LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+\/HER2\u2013) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial","volume":"34","author":"Bardia","year":"2023","journal-title":"Breast cancer, metastatic"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103061_b0700","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103061_b0705","article-title":"The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer. NPJ Precis","volume":"9","author":"Lin","year":"2025","journal-title":"Oncol"},{"key":"10.1016\/j.ctrv.2025.103061_b0710","article-title":"Mechanisms of carboplatin- and paclitaxel-dependent induction of premature senescence and pro-cancerogenic conversion of normal peritoneal mesothelium and fibroblasts","author":"Rutecki","year":"2023","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0715","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s11658-021-00287-4","article-title":"Primary high-grade serous ovarian cancer cells are sensitive to senescence induced by carboplatin and paclitaxel in vitro","volume":"26","author":"Uruski","year":"2021","journal-title":"Cell Mol Biol Lett"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0720","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-023-04604-w","article-title":"Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?","volume":"93","author":"Catalano","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103061_b0725","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0268-960X(92)90028-O","article-title":"Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies","volume":"6","author":"Hall","year":"1992","journal-title":"Blood Rev"},{"key":"10.1016\/j.ctrv.2025.103061_b0730","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bbrc.2022.07.042","article-title":"Antitumor effects of pyrrole-imidazole polyamide modified with alkylating agent on prostate cancer cells","volume":"623","author":"Funakoshi","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"issue":"24","key":"10.1016\/j.ctrv.2025.103061_b0735","doi-asserted-by":"crossref","DOI":"10.3390\/cells11244026","article-title":"Therapy-Induced Stromal Senescence Promoting Aggressiveness of Prostate and Ovarian Cancer","volume":"11","author":"Pardella","year":"2022","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103061_b0740","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.18632\/oncotarget.3040","article-title":"DNA damage induces GDNF secretion in the tumor microenvironment with paracrine effects promoting prostate cancer treatment resistance","volume":"6","author":"Huber","year":"2015","journal-title":"Oncotarget"},{"issue":"10305","key":"10.1016\/j.ctrv.2025.103061_b0745","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer","volume":"398","author":"Sandhu","year":"2021","journal-title":"Lancet"},{"issue":"49","key":"10.1016\/j.ctrv.2025.103061_b0750","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"Karantanos","year":"2013","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103061_b0755","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/iju.15424","article-title":"Exploring androgen receptor signaling pathway in prostate cancer: a path to new discoveries","volume":"31","author":"Obinata","year":"2024","journal-title":"Int J Urol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103061_b0760","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068003","article-title":"Androgen deprivation-induced senescence promotes outgrowth of androgen-refractory prostate cancer cells","volume":"8","author":"Burton","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2025.103061_b0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114765","article-title":"Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy","volume":"193","author":"Carpenter","year":"2021","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103061_b0770","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1593\/neo.11182","article-title":"Androgen depletion induces senescence in prostate cancer cells through down-regulation of Skp2","volume":"13","author":"Pernicova","year":"2011","journal-title":"Neoplasia"},{"issue":"48","key":"10.1016\/j.ctrv.2025.103061_b0775","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1038\/onc.2015.41","article-title":"CCAAT\/Enhancer binding protein beta controls androgen-deprivation-induced senescence in prostate cancer cells","volume":"34","author":"Barakat","year":"2015","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103061_b0780","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172048","article-title":"Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy","volume":"12","author":"Blute","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2025.103061_b0785","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1158\/1538-7445.AM2024-2954","article-title":"Androgen deprivation therapy (ADT) and senescence-associated secretory phenotype (SASP) in vitro: Correlation with SASP in tumor specimens as well as in the serum of patients after ADT","volume":"84","author":"Pinho-Schwermann","year":"2024","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103061_b0790","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/pros.22571","article-title":"Androgen deprivation induces senescence characteristics in prostate cancer cells in vitro and in vivo","volume":"73","author":"Ewald","year":"2013","journal-title":"Prostate"},{"issue":"10398","key":"10.1016\/j.ctrv.2025.103061_b0795","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103061_b0800","first-page":"252","article-title":"PARP inhibitors on the move in prostate cancer: spotlight on Niraparib & update on PARP inhibitor combination trials","volume":"10","author":"Beatson","year":"2022","journal-title":"Am J Clin Exp Urol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103061_b0805","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10061416","article-title":"A New Horizon for patients with Prostate Cancer","volume":"10","author":"Congregado","year":"2022","journal-title":"Biomedicines"},{"issue":"22","key":"10.1016\/j.ctrv.2025.103061_b0810","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.103061_b0815","article-title":"Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting from Biallelic BRCA2 Reversion Mutations Restores both Germline and Somatic Loss-of-Function Mutations. JCO Precis","volume":"2","author":"Carneiro","year":"2018","journal-title":"Oncol"},{"key":"10.1016\/j.ctrv.2025.103061_b0820","doi-asserted-by":"crossref","unstructured":"Darabi, S., et al., BRCA1\/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents. Medicina (Kaunas), 2022. 58(12).","DOI":"10.3390\/medicina58121818"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103061_b0825","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071593","article-title":"DNA Damage- but not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic bcl-xL Inhibitor Sensitivity","volume":"9","author":"Malaquin","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0830","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1038\/s41467-019-10460-1","article-title":"Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence","volume":"10","author":"Fleury","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2025.103061_b0835","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1158\/1538-7445.AM2025-301","article-title":"PARP inhibitor-induced senescent fibroblasts enhance prostate cancer cell proliferation and suppress NK cell-mediated cytotoxicity","volume":"85","author":"Pinho-Schwermann","year":"2025","journal-title":"Cancer Res"},{"issue":"47","key":"10.1016\/j.ctrv.2025.103061_b0840","doi-asserted-by":"crossref","first-page":"29227","DOI":"10.1039\/D1RA03820F","article-title":"CDK4\/6 inhibitors: a brief overview and prospective research directions","volume":"11","author":"Adon","year":"2021","journal-title":"RSC Adv"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103061_b0845","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.20312","article-title":"Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors with Survival in patients with Hormone Receptor-positive Metastatic Breast Cancer: a Systematic Review and Meta-analysis","volume":"3","author":"Li","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103061_b0850","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233571","article-title":"Combination cyclin-dependent kinase 4\/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a systematic review and meta-analysis","volume":"15","author":"Zheng","year":"2020","journal-title":"PLoS One"},{"issue":"48","key":"10.1016\/j.ctrv.2025.103061_b0855","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/onc.2013.83","article-title":"Targeting cell cycle and hormone receptor pathways in cancer","volume":"32","author":"Comstock","year":"2013","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103061_b0860","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1158\/1541-7786.MCR-17-0028","article-title":"CDK4\/6 Therapeutic intervention and Viable Alternative to Taxanes in CRPC","volume":"15","author":"Stice","year":"2017","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103061_b0865","doi-asserted-by":"crossref","unstructured":"Siskin, M., M.P. Economides, and D.R. Wise, Cyclin-Dependent Kinase Inhibition in Prostate Cancer: Past, Present, and Future. Cancers (Basel), 2025. 17(5).","DOI":"10.3390\/cancers17050774"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103061_b0870","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1158\/1078-0432.CCR-21-0024","article-title":"A Randomized phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer","volume":"27","author":"Palmbos","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103061_b0875","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S1470-2045(25)00475-9","article-title":"Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"26","author":"Smith","year":"2025","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103061_b0880","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","article-title":"Mechanisms of Sensitivity and Resistance to CDK4\/6 Inhibition","volume":"37","author":"Alvarez-Fernandez","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2025.103061_b0885","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-24-0903","article-title":"Harnessing senolytics and PARP inhibition to expand the antitumor activity of CDK4\/6 inhibitors in prostate cancer","author":"Brandariz","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2025.103061_b0890","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.740002","article-title":"Palbociclib Induces Senescence in Melanoma and Breast Cancer Cells and leads to Additive Growth arrest in Combination with Irradiation","volume":"11","author":"Jost","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103061_b0895","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3892\/ol.2021.12864","article-title":"Palbociclib induces cell senescence and apoptosis of gastric cancer cells by inhibiting the Notch pathway","volume":"22","author":"Bi","year":"2021","journal-title":"Oncol Lett"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103061_b0900","doi-asserted-by":"crossref","first-page":"8226","DOI":"10.18632\/oncotarget.3364","article-title":"MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition","volume":"6","author":"Kovatcheva","year":"2015","journal-title":"Oncotarget"},{"issue":"23","key":"10.1016\/j.ctrv.2025.103061_b0905","doi-asserted-by":"crossref","first-page":"E4612","DOI":"10.1073\/pnas.1705499114","article-title":"cGAS is essential for cellular senescence","volume":"114","author":"Yang","year":"2017","journal-title":"PNAS"},{"issue":"26","key":"10.1016\/j.ctrv.2025.103061_b0910","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1038\/onc.2011.485","article-title":"SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells","volume":"31","author":"Canino","year":"2012","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103061_b0915","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061908","article-title":"Stromal Senescence following Treatment with the CDK4\/6 Inhibitor Palbociclib Alters the Lung Metastatic Niche and increases Metastasis of Drug-Resistant Mammary Cancer Cells","volume":"15","author":"Gallanis","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0920","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/03915603211042335","article-title":"Radiation therapy for prostate cancer: What's the best in 2021","volume":"89","author":"Cellini","year":"2022","journal-title":"Urologia"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103061_b0925","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1096\/fba.2018-00084","article-title":"Stimulation of Prostate Cells by the Senescence Phenotype of Epithelial and Stromal Cells: Implication for Benign Prostate Hyperplasia","volume":"1","author":"Jiang","year":"2019","journal-title":"FASEB Bioadv"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103061_b0930","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/cdd.2014.97","article-title":"Radiotherapy-induced plasticity of prostate cancer mobilizes stem-like non-adherent","volume":"22","author":"Kyjacova","year":"2015","journal-title":"Erk signaling-dependent cells Cell Death Differ"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b0935","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijrobp.2017.09.037","article-title":"The Transcriptional Landscape of Radiation-Treated Human Prostate Cancer: Analysis of a prospective Tissue Cohort","volume":"100","author":"Keam","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103061_b0940","doi-asserted-by":"crossref","first-page":"595","DOI":"10.4161\/cc.6.5.3901","article-title":"A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells","volume":"6","author":"Lehmann","year":"2007","journal-title":"Cell Cycle"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103061_b0945","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/j.1349-7006.2012.02272.x","article-title":"Resveratrol enhances radiation sensitivity in prostate cancer by inhibiting cell proliferation and promoting cell senescence and apoptosis","volume":"103","author":"Fang","year":"2012","journal-title":"Cancer Sci"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103061_b0950","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103061_b0955","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s11912-025-01686-y","article-title":"Prostate Cancer Radioligand Therapy: PSMA and beyond, Current Landscape and Future Directions","volume":"27","author":"Bent","year":"2025","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ctrv.2025.103061_b0960","doi-asserted-by":"crossref","unstructured":"Carpenter, V.J., T. Saleh, and D.A. Gewirtz, Senolytics for Cancer Therapy: Is All That Glitters Really Gold? Cancers (Basel), 2021. 13(4).","DOI":"10.3390\/cancers13040723"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103061_b0965","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3390\/clinpract13040076","article-title":"The Emerging Role of Senotherapy in Cancer: a Comprehensive Review","volume":"13","author":"Malayaperumal","year":"2023","journal-title":"Clin Pract"},{"key":"10.1016\/j.ctrv.2025.103061_b0970","article-title":"Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent","volume":"11","author":"Anuar","year":"2020","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103061_b0975","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103061_b0980","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/bjh.13487","article-title":"Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies","volume":"170","author":"Roberts","year":"2015","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103061_b0985","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-11-3090","article-title":"Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer","volume":"18","author":"Rudin","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103061_b0990","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/hep.23836","article-title":"The bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib","volume":"52","author":"Hikita","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103061_b0995","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/1078-0432.CCR-10-2353","article-title":"Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models","volume":"17","author":"Tan","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103061_b1000","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104895","article-title":"Role of Bcl-2 family anti-apoptosis inhibition in overcoming therapeutic resistance in prostate cancer: a systematic review","volume":"215","author":"Jaya","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103061_b1005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120913","article-title":"Combining paclitaxel with ABT-263 has a synergistic effect on paclitaxel resistant prostate cancer cells","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS One"},{"issue":"22","key":"10.1016\/j.ctrv.2025.103061_b1010","doi-asserted-by":"crossref","first-page":"11399","DOI":"10.18632\/oncotarget.2550","article-title":"Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition","volume":"5","author":"Tamaki","year":"2014","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103061_b1015","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040831","article-title":"Preclinical Study using ABT263 to increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2\/ROS\/USP26 Axis through Altering ARv7 Protein Degradation","volume":"12","author":"Xu","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2025.103061_b1020","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116385","article-title":"Androgen deprivation-induced senescence confers sensitivity to a senolytic strategy in prostate cancer","volume":"226","author":"Carpenter","year":"2024","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103061_b1025","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1007\/s12094-022-03070-9","article-title":"Bcl-2 pathway inhibition in solid tumors: a review of clinical trials","volume":"25","author":"Ploumaki","year":"2023","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b1030","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1038\/s41598-024-55286-0","article-title":"Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate","volume":"14","author":"Kawakatsu","year":"2024","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103061_b1035","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/14656566.2023.2218545","article-title":"An update on the efficacy of Venetoclax for chronic lymphocytic leukemia","volume":"24","author":"Lovell","year":"2023","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103061_b1040","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/1078-0432.CCR-20-3260","article-title":"Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies","volume":"27","author":"Liang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103061_b1045","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.6_suppl.250","article-title":"Significance of targeting the antiapoptotic pathway in castration-sensitive prostate cancer","volume":"39","author":"Chakraborty","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103061_b1050","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.eururo.2020.10.001","article-title":"Taxane-induced Attenuation of the CXCR2\/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment","volume":"79","author":"Ruiz de Porras","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2025.103061_b1055","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.182","article-title":"Phase Ib trial of enzalutamide (Enza) with venetoclax (Ven) in metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Perimbeti","year":"2023","journal-title":"J Clin Onc"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103061_b1060","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/1078-0432.CCR-23-1525","article-title":"First-in-Human Study with Preclinical Data of BCL-2\/BCL-xL Inhibitor Pelcitoclax in locally Advanced or Metastatic Solid Tumors","volume":"30","author":"Lakhani","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103061_b1065","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030593","article-title":"Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies","volume":"9","author":"Puca","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103061_b1070","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1021\/jm1001265","article-title":"BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma\/leukemia-2 (Bcl-2) family proteins","volume":"53","author":"Wei","year":"2010","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103061_b1075","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1593\/neo.13230","article-title":"Sabutoclax (BI97C1) and BI112D1, putative inhibitors of MCL-1, induce mitochondrial fragmentation either upstream of or independent of apoptosis","volume":"15","author":"Varadarajan","year":"2013","journal-title":"Neoplasia"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103061_b1080","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1593\/neo.12640","article-title":"Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer","volume":"14","author":"Jackson","year":"2012","journal-title":"Neoplasia"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103061_b1085","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1007\/s00018-002-8498-3","article-title":"Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure","volume":"59","author":"Makarovskiy","year":"2002","journal-title":"Cell Mol Life Sci"},{"issue":"49","key":"10.1016\/j.ctrv.2025.103061_b1090","doi-asserted-by":"crossref","first-page":"19512","DOI":"10.1073\/pnas.0709443104","article-title":"Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis","volume":"104","author":"Nguyen","year":"2007","journal-title":"PNAS"},{"issue":"21","key":"10.1016\/j.ctrv.2025.103061_b1095","doi-asserted-by":"crossref","first-page":"8785","DOI":"10.1073\/pnas.1100769108","article-title":"Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7\/IL-24-mediated toxicity","volume":"108","author":"Dash","year":"2011","journal-title":"PNAS"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b1100","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1038\/s41467-022-29824-1","article-title":"Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer","volume":"13","author":"Troiani","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2025.103061_b1105","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.3027","article-title":"Mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed\/refractory solid tumors: Dose expansion results","volume":"41","author":"Carneiro","year":"2023","journal-title":"J Clin Onc"},{"issue":"20","key":"10.1016\/j.ctrv.2025.103061_b1110","doi-asserted-by":"crossref","first-page":"10832","DOI":"10.1073\/pnas.170276797","article-title":"Modulation of Akt kinase activity by binding to Hsp90","volume":"97","author":"Sato","year":"2000","journal-title":"PNAS"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103061_b1115","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.7150\/ijbs.41686","article-title":"Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K\/Akt signaling pathways","volume":"16","author":"Lu","year":"2020","journal-title":"Int J Biol Sci"},{"issue":"23\u201324","key":"10.1016\/j.ctrv.2025.103061_b1120","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1101\/gad.343129.120","article-title":"Senescence and the SASP: many therapeutic avenues","volume":"34","author":"Birch","year":"2020","journal-title":"Genes Dev"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103061_b1125","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1535-7163.MCT-19-1141","article-title":"Synthetic Lethal Metabolic Targeting of Androgen-Deprived Prostate Cancer Cells with Metformin","volume":"19","author":"Yang","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103061_b1130","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/acel.12075","article-title":"Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK\/NF-kappaB activation","volume":"12","author":"Moiseeva","year":"2013","journal-title":"Aging Cell"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103061_b1135","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/ncb3195","article-title":"MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation","volume":"17","author":"Laberge","year":"2015","journal-title":"Nat Cell Biol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103061_b1140","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ccell.2024.02.004","article-title":"Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells","volume":"42","author":"Colucci","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b1145","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41392-023-01343-5","article-title":"Cellular rejuvenation: molecular mechanisms and potential therapeutic interventions for diseases","volume":"8","author":"Ji","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103061_b1150","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/s43018-022-00462-2","article-title":"cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis","volume":"3","author":"Wang","year":"2022","journal-title":"Nat Cancer"},{"issue":"21","key":"10.1016\/j.ctrv.2025.103061_b1155","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-18-0549","article-title":"Tyrosine Kinase Inhibitors increase MCL1 Degradation and in Combination with BCLXL\/BCL2 Inhibitors Drive Prostate Cancer Apoptosis","volume":"24","author":"Arai","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b1160","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1038\/s41467-022-35657-9","article-title":"Targeting anti-apoptotic pathways eliminates senescent melanocytes and leads to nevi regression","volume":"13","author":"Kohli","year":"2022","journal-title":"Nat Commun"},{"issue":"7668","key":"10.1016\/j.ctrv.2025.103061_b1165","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.ctrv.2025.103061_b1170","doi-asserted-by":"crossref","DOI":"10.1172\/JCI158450","article-title":"Cellular senescence: a key therapeutic target in aging and diseases","volume":"132","author":"Zhang","year":"2022","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b1175","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s13046-022-02555-3","article-title":"Cellular senescence in cancer: clinical detection and prognostic implications","volume":"41","author":"Domen","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"35","key":"10.1016\/j.ctrv.2025.103061_b1180","doi-asserted-by":"crossref","first-page":"15152","DOI":"10.1002\/anie.202004142","article-title":"Real-Time In Vivo Detection of Cellular Senescence through the Controlled Release of the NIR Fluorescent Dye Nile Blue","volume":"59","author":"Lozano-Torres","year":"2020","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.ctrv.2025.103061_b1185","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-CT095","volume":"83","author":"LaFougere","year":"2023","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103061_b1190","doi-asserted-by":"crossref","first-page":"14170","DOI":"10.1038\/s41598-020-71042-6","article-title":"Depletion of senescent-like neuronal cells alleviates cisplatin-induced peripheral neuropathy in mice","volume":"10","author":"Acklin","year":"2020","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103061_b1195","doi-asserted-by":"crossref","DOI":"10.1111\/acel.14037","article-title":"Senolytic treatment alleviates doxorubicin-induced chemobrain","volume":"23","author":"Budamagunta","year":"2024","journal-title":"Aging Cell"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T08:03:51Z","timestamp":1767168231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225001835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":239,"alternative-id":["S0305737225001835"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103061","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cellular senescence: A novel mechanism of therapeutic resistance in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103061"}}